Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib</title><author><name sortKey="Hughes, Timothy P" sort="Hughes, Timothy P" uniqKey="Hughes T" first="Timothy P." last="Hughes">Timothy P. Hughes</name><affiliation><nlm:aff id="aff1">South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, SA, Australia;</nlm:aff></affiliation><affiliation><nlm:aff id="aff2">Division of Haematology and Centre for Cancer Biology, South Australian Pathology, Adelaide, SA, Australia;</nlm:aff></affiliation></author><author><name sortKey="Saglio, Giuseppe" sort="Saglio, Giuseppe" uniqKey="Saglio G" first="Giuseppe" last="Saglio">Giuseppe Saglio</name><affiliation><nlm:aff id="aff3">University of Turin, Orbassano, Italy;</nlm:aff></affiliation></author><author><name sortKey="Kantarjian, Hagop M" sort="Kantarjian, Hagop M" uniqKey="Kantarjian H" first="Hagop M." last="Kantarjian">Hagop M. Kantarjian</name><affiliation><nlm:aff id="aff4">The University of Texas MD Anderson Cancer Center, Houston, TX;</nlm:aff></affiliation></author><author><name sortKey="Guilhot, Francois" sort="Guilhot, Francois" uniqKey="Guilhot F" first="François" last="Guilhot">François Guilhot</name><affiliation><nlm:aff id="aff5">Institut National de la Santé et de la Recherche Médicale Centre d'Investigation Clinique 0802, Centre Hospitalier Universitaire de Poitiers, Poitiers, France;</nlm:aff></affiliation></author><author><name sortKey="Niederwieser, Dietger" sort="Niederwieser, Dietger" uniqKey="Niederwieser D" first="Dietger" last="Niederwieser">Dietger Niederwieser</name><affiliation><nlm:aff id="aff6">University of Leipzig, Leipzig, Saxony, Germany;</nlm:aff></affiliation></author><author><name sortKey="Rosti, Gianantonio" sort="Rosti, Gianantonio" uniqKey="Rosti G" first="Gianantonio" last="Rosti">Gianantonio Rosti</name><affiliation><nlm:aff id="aff7">University of Bologna, Bologna, Italy;</nlm:aff></affiliation></author><author><name sortKey="Nakaseko, Chiaki" sort="Nakaseko, Chiaki" uniqKey="Nakaseko C" first="Chiaki" last="Nakaseko">Chiaki Nakaseko</name><affiliation><nlm:aff id="aff8">Chiba University Hospital, Chiba, Japan;</nlm:aff></affiliation></author><author><name sortKey="De Souza, Carmino Antonio" sort="De Souza, Carmino Antonio" uniqKey="De Souza C" first="Carmino Antonio" last="De Souza">Carmino Antonio De Souza</name><affiliation><nlm:aff id="aff9">University of Campinas, Campinas, Brazil;</nlm:aff></affiliation></author><author><name sortKey="Kalaycio, Matt E" sort="Kalaycio, Matt E" uniqKey="Kalaycio M" first="Matt E." last="Kalaycio">Matt E. Kalaycio</name><affiliation><nlm:aff id="aff10">Cleveland Clinic, Cleveland, OH;</nlm:aff></affiliation></author><author><name sortKey="Meier, Stephan" sort="Meier, Stephan" uniqKey="Meier S" first="Stephan" last="Meier">Stephan Meier</name><affiliation><nlm:aff id="aff11">Novartis Pharma AG, Basel, Switzerland;</nlm:aff></affiliation></author><author><name sortKey="Fan, Xiaolin" sort="Fan, Xiaolin" uniqKey="Fan X" first="Xiaolin" last="Fan">Xiaolin Fan</name><affiliation><nlm:aff id="aff12">Novartis Pharmaceuticals Corporation, East Hanover, NJ;</nlm:aff></affiliation></author><author><name sortKey="Menssen, Hans D" sort="Menssen, Hans D" uniqKey="Menssen H" first="Hans D." last="Menssen">Hans D. Menssen</name><affiliation><nlm:aff id="aff11">Novartis Pharma AG, Basel, Switzerland;</nlm:aff></affiliation></author><author><name sortKey="Larson, Richard A" sort="Larson, Richard A" uniqKey="Larson R" first="Richard A." last="Larson">Richard A. Larson</name><affiliation><nlm:aff wicri:cut="; and" id="aff13">University of Chicago, Chicago, IL</nlm:aff></affiliation></author><author><name sortKey="Hochhaus, Andreas" sort="Hochhaus, Andreas" uniqKey="Hochhaus A" first="Andreas" last="Hochhaus">Andreas Hochhaus</name><affiliation><nlm:aff id="aff14">Abteilung Hämatologie/Onkologie, Universitätsklinikum Jena, Jena, Thuringia, Germany</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">24335106</idno><idno type="pmc">4624459</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624459</idno><idno type="RBID">PMC:4624459</idno><idno type="doi">10.1182/blood-2013-06-510396</idno><date when="2014">2014</date><idno type="wicri:Area/Pmc/Corpus">000172</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000172</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib</title><author><name sortKey="Hughes, Timothy P" sort="Hughes, Timothy P" uniqKey="Hughes T" first="Timothy P." last="Hughes">Timothy P. Hughes</name><affiliation><nlm:aff id="aff1">South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, SA, Australia;</nlm:aff></affiliation><affiliation><nlm:aff id="aff2">Division of Haematology and Centre for Cancer Biology, South Australian Pathology, Adelaide, SA, Australia;</nlm:aff></affiliation></author><author><name sortKey="Saglio, Giuseppe" sort="Saglio, Giuseppe" uniqKey="Saglio G" first="Giuseppe" last="Saglio">Giuseppe Saglio</name><affiliation><nlm:aff id="aff3">University of Turin, Orbassano, Italy;</nlm:aff></affiliation></author><author><name sortKey="Kantarjian, Hagop M" sort="Kantarjian, Hagop M" uniqKey="Kantarjian H" first="Hagop M." last="Kantarjian">Hagop M. Kantarjian</name><affiliation><nlm:aff id="aff4">The University of Texas MD Anderson Cancer Center, Houston, TX;</nlm:aff></affiliation></author><author><name sortKey="Guilhot, Francois" sort="Guilhot, Francois" uniqKey="Guilhot F" first="François" last="Guilhot">François Guilhot</name><affiliation><nlm:aff id="aff5">Institut National de la Santé et de la Recherche Médicale Centre d'Investigation Clinique 0802, Centre Hospitalier Universitaire de Poitiers, Poitiers, France;</nlm:aff></affiliation></author><author><name sortKey="Niederwieser, Dietger" sort="Niederwieser, Dietger" uniqKey="Niederwieser D" first="Dietger" last="Niederwieser">Dietger Niederwieser</name><affiliation><nlm:aff id="aff6">University of Leipzig, Leipzig, Saxony, Germany;</nlm:aff></affiliation></author><author><name sortKey="Rosti, Gianantonio" sort="Rosti, Gianantonio" uniqKey="Rosti G" first="Gianantonio" last="Rosti">Gianantonio Rosti</name><affiliation><nlm:aff id="aff7">University of Bologna, Bologna, Italy;</nlm:aff></affiliation></author><author><name sortKey="Nakaseko, Chiaki" sort="Nakaseko, Chiaki" uniqKey="Nakaseko C" first="Chiaki" last="Nakaseko">Chiaki Nakaseko</name><affiliation><nlm:aff id="aff8">Chiba University Hospital, Chiba, Japan;</nlm:aff></affiliation></author><author><name sortKey="De Souza, Carmino Antonio" sort="De Souza, Carmino Antonio" uniqKey="De Souza C" first="Carmino Antonio" last="De Souza">Carmino Antonio De Souza</name><affiliation><nlm:aff id="aff9">University of Campinas, Campinas, Brazil;</nlm:aff></affiliation></author><author><name sortKey="Kalaycio, Matt E" sort="Kalaycio, Matt E" uniqKey="Kalaycio M" first="Matt E." last="Kalaycio">Matt E. Kalaycio</name><affiliation><nlm:aff id="aff10">Cleveland Clinic, Cleveland, OH;</nlm:aff></affiliation></author><author><name sortKey="Meier, Stephan" sort="Meier, Stephan" uniqKey="Meier S" first="Stephan" last="Meier">Stephan Meier</name><affiliation><nlm:aff id="aff11">Novartis Pharma AG, Basel, Switzerland;</nlm:aff></affiliation></author><author><name sortKey="Fan, Xiaolin" sort="Fan, Xiaolin" uniqKey="Fan X" first="Xiaolin" last="Fan">Xiaolin Fan</name><affiliation><nlm:aff id="aff12">Novartis Pharmaceuticals Corporation, East Hanover, NJ;</nlm:aff></affiliation></author><author><name sortKey="Menssen, Hans D" sort="Menssen, Hans D" uniqKey="Menssen H" first="Hans D." last="Menssen">Hans D. Menssen</name><affiliation><nlm:aff id="aff11">Novartis Pharma AG, Basel, Switzerland;</nlm:aff></affiliation></author><author><name sortKey="Larson, Richard A" sort="Larson, Richard A" uniqKey="Larson R" first="Richard A." last="Larson">Richard A. Larson</name><affiliation><nlm:aff wicri:cut="; and" id="aff13">University of Chicago, Chicago, IL</nlm:aff></affiliation></author><author><name sortKey="Hochhaus, Andreas" sort="Hochhaus, Andreas" uniqKey="Hochhaus A" first="Andreas" last="Hochhaus">Andreas Hochhaus</name><affiliation><nlm:aff id="aff14">Abteilung Hämatologie/Onkologie, Universitätsklinikum Jena, Jena, Thuringia, Germany</nlm:aff></affiliation></author></analytic><series><title level="j">Blood</title><idno type="ISSN">0006-4971</idno><idno type="eISSN">1528-0020</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><title>Key Points</title><p><list list-type="bullet"><list-item><p>More patients with chronic myeloid leukemia in chronic phase achieve EMR on frontline nilotinib than imatinib.</p></list-item><list-item><p>EMR failure on frontline nilotinib or imatinib predicts poor outcomes in patients with chronic myeloid leukemia in chronic phase.</p></list-item></list></p></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Blood</journal-id><journal-id journal-id-type="iso-abbrev">Blood</journal-id><journal-id journal-id-type="hwp">bloodjournal</journal-id><journal-id journal-id-type="pmc">blood</journal-id><journal-id journal-id-type="publisher-id">Blood</journal-id><journal-title-group><journal-title>Blood</journal-title></journal-title-group><issn pub-type="ppub">0006-4971</issn><issn pub-type="epub">1528-0020</issn><publisher><publisher-name>American Society of Hematology</publisher-name><publisher-loc>Washington, DC</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24335106</article-id><article-id pub-id-type="pmc">4624459</article-id><article-id pub-id-type="publisher-id">2013/510396</article-id><article-id pub-id-type="doi">10.1182/blood-2013-06-510396</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>29</subject><subject>33</subject></subj-group><subj-group subj-group-type="heading"><subject>Myeloid Neoplasia</subject></subj-group></article-categories><title-group><article-title>Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Hughes</surname><given-names>Timothy P.</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Saglio</surname><given-names>Giuseppe</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Kantarjian</surname><given-names>Hagop M.</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Guilhot</surname><given-names>François</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Niederwieser</surname><given-names>Dietger</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Rosti</surname><given-names>Gianantonio</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Nakaseko</surname><given-names>Chiaki</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>De Souza</surname><given-names>Carmino Antonio</given-names></name><xref ref-type="aff" rid="aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Kalaycio</surname><given-names>Matt E.</given-names></name><xref ref-type="aff" rid="aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Meier</surname><given-names>Stephan</given-names></name><xref ref-type="aff" rid="aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Fan</surname><given-names>Xiaolin</given-names></name><xref ref-type="aff" rid="aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Menssen</surname><given-names>Hans D.</given-names></name><xref ref-type="aff" rid="aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Larson</surname><given-names>Richard A.</given-names></name><xref ref-type="aff" rid="aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Hochhaus</surname><given-names>Andreas</given-names></name><xref ref-type="aff" rid="aff14">14</xref></contrib><aff id="aff1"><label>1</label>South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, SA, Australia;</aff><aff id="aff2"><label>2</label>Division of Haematology and Centre for Cancer Biology, South Australian Pathology, Adelaide, SA, Australia;</aff><aff id="aff3"><label>3</label>University of Turin, Orbassano, Italy;</aff><aff id="aff4"><label>4</label>The University of Texas MD Anderson Cancer Center, Houston, TX;</aff><aff id="aff5"><label>5</label>Institut National de la Santé et de la Recherche Médicale Centre d'Investigation Clinique 0802, Centre Hospitalier Universitaire de Poitiers, Poitiers, France;</aff><aff id="aff6"><label>6</label>University of Leipzig, Leipzig, Saxony, Germany;</aff><aff id="aff7"><label>7</label>University of Bologna, Bologna, Italy;</aff><aff id="aff8"><label>8</label>Chiba University Hospital, Chiba, Japan;</aff><aff id="aff9"><label>9</label>University of Campinas, Campinas, Brazil;</aff><aff id="aff10"><label>10</label>Cleveland Clinic, Cleveland, OH;</aff><aff id="aff11"><label>11</label>Novartis Pharma AG, Basel, Switzerland;</aff><aff id="aff12"><label>12</label>Novartis Pharmaceuticals Corporation, East Hanover, NJ;</aff><aff id="aff13"><label>13</label>University of Chicago, Chicago, IL; and</aff><aff id="aff14"><label>14</label>Abteilung Hämatologie/Onkologie, Universitätsklinikum Jena, Jena, Thuringia, Germany</aff></contrib-group><pub-date pub-type="ppub"><day>27</day><month>2</month><year>2014</year></pub-date><pub-date pub-type="epreprint"><day>11</day><month>12</month><year>2013</year></pub-date><pub-date pub-type="pmc-release"><day>27</day><month>2</month><year>2014</year></pub-date><pmc-comment> PMC Release delay is 0 months and 0 days and was based on the
<volume>123</volume><issue>9</issue><fpage>1353</fpage><lpage>1360</lpage><history><date date-type="received"><day>25</day><month>6</month><year>2013</year></date><date date-type="accepted"><day>17</day><month>11</month><year>2013</year></date></history><permissions><copyright-statement>© 2014 by The American Society of Hematology</copyright-statement><copyright-year>2014</copyright-year></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="1353.pdf"></self-uri><abstract abstract-type="executive-summary"><title>Key Points</title><p><list list-type="bullet"><list-item><p>More patients with chronic myeloid leukemia in chronic phase achieve EMR on frontline nilotinib than imatinib.</p></list-item><list-item><p>EMR failure on frontline nilotinib or imatinib predicts poor outcomes in patients with chronic myeloid leukemia in chronic phase.</p></list-item></list></p></abstract><abstract><p>We explored the impact of early molecular response (EMR; <italic>BCR-ABL</italic> ≤10% on the international scale [BCR-ABL<sup>IS</sup>] at 3 or 6 months) on outcomes in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with nilotinib or imatinib based on 4 years of follow up in Evaluating Nilotinib Efficacy and Safety in Clinical Trials—Newly Diagnosed Patients. Patients (n = 846) received nilotinib 300 mg twice daily, nilotinib 400 mg twice daily, or imatinib 400 mg once daily. At 3 months, more patients had EMR failure (ie, BCR-ABL<sup>IS</sup> >10%) on imatinib (33%) than on nilotinib (9%-11%); similarly at 6 months, 16% of patients in the imatinib arm vs 3% and 7% in the nilotinib arms had EMR failure. In all arms, EMR failure was associated with lower rates of molecular response, an increased risk of progression, and lower overall survival compared with EMR achievement. We also analyzed patient and treatment characteristics associated with EMR and found distinct patterns in the nilotinib arms vs the imatinib arm. High Sokal risk score was associated with a high rate of EMR failure on imatinib, but not on nilotinib. In contrast, reduced dose intensity and dose interruptions were strongly associated with EMR failure in nilotinib-treated, but not imatinib-treated, patients. This study is registered at <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link> as #NCT00471497.</p></abstract><counts><page-count count="8"></page-count></counts><custom-meta-group><custom-meta><meta-name>access</meta-name><meta-value>free</meta-value></custom-meta></custom-meta-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000172 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000172 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |